BOSTON: Scientists have launched the first human clinical trial of an anti-aging gene therapy, marking a historic step in biotechnology, according to US-based Life Biosciences.
The company announced on June 9 that a volunteer has successfully received the experimental treatment in its initial human trial.
The therapy is designed to reduce the effects of aging at the cellular level using “cellular reprogramming” technology, which aims to restore older cells to a more youthful state so they can function more effectively.
In early stages, the treatment is being tested for eye-related conditions, including glaucoma and other vision disorders, where it is intended to reactivate damaged cells and improve their function.
Researchers say the approach works by using specific genetic factors, known as Yamanaka factors, to reset the epigenetic programming of cells, potentially reversing aspects of cellular aging. The process is tightly controlled to minimize safety risks.
Experts emphasize that the trial is still in its early phase and is primarily focused on safety and initial effectiveness.
However, if successful, the therapy could pave the way for major advances in treating age-related diseases and significantly extending healthy human lifespan in the future.
More read, Russia develops potential anti-aging vaccine to slow cellular decay
Earlier, Russia has announced a major scientific development with the introduction of a potential “anti-aging vaccine,” a gene therapy designed to slow cellular deterioration by targeting the RAGE receptor considered a key driver of age-related changes in the human body.
Researchers have reportedly carried out experimental procedures aimed at blocking this receptor, with the goal of halting biological processes linked to aging and extending cellular longevity.
The project is being developed by the Institute of Aging Biology and Medicine as part of the country’s broader push to strengthen domestic biotechnology capabilities.
Officials say the initiative is also intended to address the economic and social challenges posed by Russia’s aging and declining population.
